Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Amgen’s LUMAKRAS and Vectibix combination has received approval from the US FDA for treating KRAS G12C-mutated mCRC.

Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras (sotorasib), in combination with its anti-EGFR antibody, Vectibix (panitumumab), for treating KRAS G12C-mutated ...

The U.S. Food and Drug Administration (FDA) has approved Amgen’s (NASDAQ:AMGN) KRAS G12C inhibitor Lumakras as part of a combination regimen for adults with metastatic colorectal cancer (mCRC ...

The FDA has approved Amgen’s Lumakras in combination with Vectibix (panitumumab) to treat adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) previously treated with ...

The decision, announced Thursday, applies to adults whose tumors carry the KRAS G12C mutation. Amgen's treatment pairs Lumakras (sotorasib) with Vectibix (panitumumab), an epidermal growth factor ...

in first-line treatment of mCRC for patients with wild-type KRAS mCRC. Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against ...

Amgen announced that the US Food and Drug Administration (FDA) has approved Lumakras (sotorasib) in combination with Vectibix (panitumumab) for the treatment of adult patients with KRAS G12C-mutated ...